Exabis Library
Welcome to the e-CCO Library!
P509: Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P509: IBD cancer and serious infections in Europe (I-CARE): a European prospective observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P509: Influence of concomitant immunosuppresives in retention rate in Crohn´s Disease patients under ustekinumab in the SUSTAIN Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P509: Long-term outcomes in biologic-treated perianal Crohn’s fistula
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P509: Long-term outcomes of adalimumab in patients with Crohn’s disease: Can a doubled dose of adalimumab improve outcomes?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P509: Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P509: What is the effect of inflammatory bowel disease on sedation rates at colonoscopy?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P510: Assessment of study group – patients with inflammatory bowel disease, treated with monoclonal anti-TNF alpha: a multicenter, prospective cohort observational study, Satimos – preliminary report in pediatric population
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P510: Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P510: Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P510: Infliximab in the very young: it is all about the dosing – a multi-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P510: Postoperative enterocoutaneous fistula after surgery for Crohn’s disease performed in a tertiary centre over 15 years: analysis of the long-term outcomes and predictors of fistula closure
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P510: Skin anergy and latent tuberculosis in inflammatory bowel disease patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P511: Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P511: Disease-specific risk factors for malnutrition development in IBD
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P511: Early prediction of steroid failure in acute severe ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P511: Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapy
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM